PULM - Pulmatrix, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
0.530073
-0.019747 (-3.59%)
At close: 3:59PM EDT

0.526000 -0.00 (-0.77%)
After hours: 4:07PM EDT

Stock chart is not supported by your current browser
Previous Close0.549820
Open0.550000
Bid0.420000 x 800
Ask0.590000 x 3100
Day's Range0.506800 - 0.550000
52 Week Range0.410000 - 2.670000
Volume311,942
Avg. Volume1,487,961
Market Cap22.224M
Beta3.71
PE Ratio (TTM)N/A
EPS (TTM)-0.959000
Earnings DateMay 3, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • PR Newswire22 days ago

    Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    All doses were well tolerated in normal healthy volunteers in Parts 1 and 2 at up to 35 mg of itraconazole, the maximal dose planned Substantially lower systemic exposure (100- to 400-fold) was observed ...

  • Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients
    PR Newswirelast month

    Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients

    LEXINGTON, Mass., June 13, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the publication of data from a dose-ranging Phase 1 clinical study of PUR0200 in COPD patients. PUR0200 is a once-daily, reformulation of tiotropium bromide for COPD patients and is being developed as a branded alternative to Spiriva® HandiHaler®. In the published study, moderate-to-severe COPD patients were administered one of three PUR0200 doses (3mg, 6mg or 9mg tiotropium bromide), Spiriva HandiHaler (18mg tiotropium bromide) or placebo in a 5 period cross-over study design.

  • Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders
    PR Newswirelast month

    Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders

    Election of three directors (Steven Gillis, Ph.D., Terrance G. McGuire and Amit D. Munshi) to serve as Class I directors on the company's Board of Directors to serve until the 2021 Annual Meeting of Stockholders or until successors have been duly elected and qualified. Amendment of the Company's Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan to (i) increase the total number of shares of common stock authorized for issuance under such plan to 12,500,000 shares and (ii) modify such plan's "evergreen" provision so that on January 1st of each year the number of shares reserved for issuance under such plan will automatically increase by 5% of the number of outstanding shares of common stock on such date. Amendment of the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000 shares.

  • ACCESSWIRElast month

    Wired News - Madrigal Pharma Reported Encouraging Top-line Data at 36 Weeks from Phase-2 Clinical Trial of MGL-3196 in Patients with NASH

    LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want access to our free research report on Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MDGL as the Company's latest news hit the wire. On May 31, 2018, the Company announced positive top-line, 36-week results from a Phase-2 clinical trial assessing MGL-3196, a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist, in patients with biopsy-proven non-alcoholic steatohepatitis (NASH). Active-Investors.com is currently working on the research report for Pulmatrix, Inc. (NASDAQ: PULM), which also belongs to the Healthcare sector as the Company Madrigal Pharma.

  • ACCESSWIRElast month

    Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities

    Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Proteostasis Therapeutics Inc. (NASDAQ: PTI), Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), and Pulmatrix Inc. (NASDAQ: PULM).

  • Interested In Pulmatrix Inc (NASDAQ:PULM)? Here’s How It Performed Recently
    Simply Wall St.2 months ago

    Interested In Pulmatrix Inc (NASDAQ:PULM)? Here’s How It Performed Recently

    In this commentary, I will examine Pulmatrix Inc’s (NASDAQ:PULM) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, as wellRead More...

  • Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego
    PR Newswire2 months ago

    Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego

    LEXINGTON, Mass., May 17, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases has been selected to present at the 2018 Respiratory Innovation Summit at the Manchester Grand Hyatt in San Diego.  Pulmatrix CEO Robert Clarke, PhD, will present the company profile in the Drug Delivery & Diagnostics Company Showcase at 10:50AM PDT on May 19, 2018.

  • Pulmatrix Reports Q1 2018 Results
    PR Newswire2 months ago

    Pulmatrix Reports Q1 2018 Results

    LEXINGTON, Mass. , May 11, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone for our Pulmazole program in the first quarter ...

  • Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering
    PR Newswire4 months ago

    Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering

    LEXINGTON, Mass., March 29, 2018 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units. Each unit is comprised of one share of common stock (or common stock equivalent), one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock.

  • Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline
    PR Newswire4 months ago

    Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline

    LEXINGTON, Mass. , March 13, 2018 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary ...

  • Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?
    Simply Wall St.4 months ago

    Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?

    Investors are always looking for growth in small-cap stocks like Pulmatrix Inc (NASDAQ:PULM), with a market cap of US$31.15M. However, an important fact which most ignore is: how financially healthyRead More...

  • Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
    PR Newswire5 months ago

    Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    ABPA is a disease that occurs most often in patients with underlying asthma or cystic fibrosis, and it is characterized by an exaggerated allergic hypersensitivity response of the immune system to the fungus Aspergillus growing in the airways. Oral itraconazole (Sporanox®) is currently used as an adjunctive treatment to corticosteroids in ABPA patients.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix

    NEW YORK, NY / ACCESSWIRE / January 29, 2018 / All three major indexes closed the week at record highs Friday as corporate earnings continue to impress investors. The Dow Jones Industrial Average gained ...

  • Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?
    Simply Wall St.6 months ago

    Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?

    Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM over the last few months. As aRead More...

  • Zacks Small Cap Research6 months ago

    PULM: MHRA Authorizes CTA; Patient Screening Commences!

    By Anita Dushyanth, PhD NASDAQ:PULM Pulmatrix (NASDAQ:PULM) management filed a Clinical Trial Application (CTA) in 2H 2017 in the EU to support a Phase 1/1b trial in healthy volunteers and asthmatics, ...

  • Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018
    PR Newswire6 months ago

    Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018

    LEXINGTON, Mass., Jan. 24, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it will present new preclinical data for Pulmazole (PUR1900), its inhaled antifungal drug, in a poster at the 8th Advances Against Aspergillosis Conference in Lisbon, Portugal. In a preclinical model of invasive aspergillosis, Pulmazole treatment by inhalation resulted in a significant prolongation of survival and improved clinical signs of infection compared to placebo treatment. "The preclinical efficacy data highlights the potential advantages of Pulmazole in treating pulmonary Aspergillus infections by delivering itraconazole directly to the lungs," said David Hava, Ph.D., Chief Scientific Officer for Pulmatrix.

  • Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
    PR Newswire6 months ago

    Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    ABPA is a disease that occurs most often in patients with underlying asthma or cystic fibrosis, and it is characterized by an exaggerated allergic hypersensitivity response of the immune system to the fungus Aspergillus growing in the airways. Oral itraconazole (Sporanox®) is currently used as an adjunctive treatment to corticosteroids in ABPA patients.

  • How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?
    Simply Wall St.7 months ago

    How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?

    Examining Pulmatrix Inc’s (NASDAQ:PULM) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, whichRead More...

  • Pulmatrix Inc (PULM): Time For A Financial Health Check
    Simply Wall St.7 months ago

    Pulmatrix Inc (PULM): Time For A Financial Health Check

    While small-cap stocks, such as Pulmatrix Inc (NASDAQ:PULM) with its market cap of USD $34.31M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube8 months ago

    Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Pulmatrix, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Pulmatrix, Inc. – Regeneron Pharmaceuticals, Inc., Nektar Therapeutics and GlycoMimetics, Inc. (REGN-US, NKTR-US and GLYC-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.34 ... Read more (Read more...)

  • PULM: Business And Financial Update For Third Quarter 2017
    Zacks Small Cap Research8 months ago

    PULM: Business And Financial Update For Third Quarter 2017

    On November 9, 2017 Pulmatrix (PULM) announced their third quarter financial results and provided operational highlights. As a reminder, the global ABPA-asthma market is a multi-billion dollar opportunity with the U.S. representing close to two-thirds (~60%) of this industry.  Management expects the Phase I studies supporting the PUR1900 program in both CF and severe asthma patients to create partnership opportunities for both indications.

  • Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials
    PR Newswire8 months ago

    Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials

    Completed Out-License Agreement for PUR0200 US Rights and Received Award to Advance Development of Pulmazole LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) today reports ...

  • Pulmatrix Presents at the North American Cystic Fibrosis Conference
    PR Newswire8 months ago

    Pulmatrix Presents at the North American Cystic Fibrosis Conference

    Preclinical data show that Pulmatrix's inhaled antifungal drug can achieve high concentrations in the lungs, with low levels in the bloodstream LEXINGTON, Mass. , Oct. 31, 2017 /PRNewswire/ --  Pulmatrix, ...

  • Pulmatrix Appoints Dr. James Roach as Chief Medical Officer
    PR Newswire9 months ago

    Pulmatrix Appoints Dr. James Roach as Chief Medical Officer

    Dr. Roach will lead the clinical development of Pulmatrix's innovative inhaled drugs for serious lung diseases, including allergic bronchopulmonary aspergillosis (ABPA) and chronic obstructive lung disease (COPD).

  • ACCESSWIRE9 months ago

    Pulmatrix: Company to Watch in Lung Disease Market

    SAN DIEGO, CA / ACCESSWIRE / October 24, 2017 / CEOCFO Magazine , an independent investment publication that highlights important technologies and companies, today focuses on the huge markets for drug ...